Stability of T Cell and NK Cell Profiles in Peripheral Blood Mononuclear Cells After Multiple Immune Cell Therapy Sessions

Immunotherapy represents a significant advancement in oncology, characterized by the ex vivo expansion of innate and adaptive immune cells to combat cancer. Despite its demonstrated efficacy in both preclinical and clinical studies, assessing the immune system's response through peripheral blood mononuclear cells (PBMC) post-therapy remains crucial. This study examined the expression profiles of T cell and NK cell markers in the PBMC of healthy individuals and cancer patients (breast, lung, and colon cancer) following five immune cell therapy sessions using flow cytometry, specifically evaluating cells with T cell (CD3 and CD8) and NK Cell (CD56 and NKG2D) markers. The results indicated no substantial changes in the proportions of CD3 + and CD8 + for T cells, nor NK cells expressing CD56 and NKG2D, across healthy subjects, and patients with breast, lung, and colon cancer after five sessions of immune cell therapy. These findings suggest that immune cell therapy does not induce significant alterations in T cell populations or NK cell activity, thereby preserving immune system homeostasis. Consequently, this research supports the notion that immune cell therapy operates effectively and safely, without disrupting immune equilibrium, and offers valuable insights for the development of enhanced cancer treatment modalities in the future.